Eli Lilly’s mirikizumab scores positive data in Phase II Crohn’s study
Category: #health  By Mateen Dalal  Date: 2019-05-24
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly’s mirikizumab scores positive data in Phase II Crohn’s study

The company plans to initiate Phase III trials to assess mirikizumab’s benefit-risk profile to cure Crohn’s disease.

U.S. pharma giant, Eli Lilly and Co. has recently announced positive data from the Serenity Phase II study that evaluated the efficacy and safety of mirikizumab in patients with moderately to severely active Crohn’s disease.

According to the drug maker, patients treated with investigational antibody mirikizumab achieved reductions in clinical and endoscopic measures of disease activity after 12 weeks compared to placebo. Meanwhile, the maintenance phase of this study is currently ongoing.

Reportedly, in the study, patients with moderately- to severely active Crohn’s disease were randomized to receive either placebo or one of three doses of mirikizumab, which, for the record, is a trial-based antibody that targets the p19 subunit of interleukin 23.

The trial’s primary endpoint assessed mirikizumab against placebo on endoscopic response, which was identified as a 50% reduction from baseline in the severity of individual patient’s disease. Meanwhile, secondary endpoints contained clinical remission as measured by PRO (Patient Reported Outcomes) remission, endoscopic remission, and safety.

Speaking on the results, Lotus Mallbris, Vice-President, Immunology Development, Eli Lilly and Co., said that the company, following its last year’s presentation of positive Phase II results for mirikizumab for the treatment of moderate to severe ulcerative colitis, is delighted to return to DDW to display more positive data for mirikizumab in patients with chronic, inflammatory gastrointestinal diseases.

She said that their firm, while continuing to advance the science of gastroenterology, is hopeful that mirikizumab will help to raise the standard and make remission conceivable for patients living with immune-mediated illnesses like Crohn’s disease.

Reliable reports claim that Elli Lilly is planning to initiate Phase III trials to assess mirikizumab’s benefit-risk profile to cure Crohn’s disease. Whereas mirikizumab, which binds to the p19 subunit of interleukin 23, is being studied for the treatment of immune diseases, including ulcerative colitis, psoriasis, and Crohn’s disease.

Source Credit: https://www.drugdevelopment-technology.com/news/lilly-reports-positive-data-from-phase-ii-study-of-mirikizumab/

https://pharmaceutical-business-review.com/news/lillys-mirikizumab-succeeds-in-phase-2-study-in-crohns-disease/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Lufthansa Group to swap old A340 planes with 10 new long-haul jets

Lufthansa Group to swap old A340 planes with 10 new long-haul jets

By Mateen Dalal

The parent company of German airline Deutsche Lufthansa AG, Lufthansa Group, reportedly said it would purchase a total of 10 long-haul aircraft, including 5 Boeing B787-9s and 5 Airbus A350-900s, to replace aging Airbus A340 planes in an effort to mo...

Facebook, Google sign content deals with Australia’s Seven West Media

Facebook, Google sign content deals with Australia’s Seven West Media

By Mateen Dalal

Seven West Media, an Australian newspaper and television firm, has reportedly signed a content deal with Facebook Inc. and Google LLC in the wake of recent landmark laws that have enabled the industry to obtain new revenue sources and adapt to the in...

Microsoft considered reducing Xbox Store fee to revive console gaming

Microsoft considered reducing Xbox Store fee to revive console gaming

By Mateen Dalal

Multinational tech-giant Microsoft was reportedly looking to lower its Xbox store commission fee to a meager 12% from the previous 30%, as per confidential documents submitted in the Epic Games and Apple case. The document from January also contains...